BioAtla, Inc. Reports Q2 2025 Financial Results and Clinical Progress

Bioatla, Inc. ( (BCAB) ) has released its Q2 earnings. Here is a breakdown of the information Bioatla, Inc. presented to its investors.

BioAtla, Inc. is a global clinical-stage biotechnology company specializing in the development of conditionally active biologic antibody therapeutics for the treatment of solid tumors, utilizing its proprietary CAB platform technology.

In its second quarter 2025 financial results, BioAtla reported ongoing progress in its clinical programs, including the Phase 1 dose-escalation study of its CAB-EpCAM x CAB-CD3 bispecific T-cell engager (BA3182) and the Phase 2 study of the fast track designated Ozurift amab vedotin (Oz-V). The company is also advancing partnering discussions with the aim of closing at least one transaction by the end of the year.

Key financial highlights include a decrease in research and development expenses to $13.7 million from $16.2 million in the same quarter of 2024, primarily due to workforce reductions and program prioritization efforts. General and administrative expenses also decreased to $5.0 million from $5.8 million. The net loss for the quarter was $18.7 million, an improvement from the $21.1 million net loss in the previous year. Cash and cash equivalents stood at $18.2 million as of June 30, 2025.

Strategically, BioAtla is focused on advancing its clinical trials, with a Phase 1 data readout for BA3182 expected in the second half of 2025 and a planned meeting with the FDA for Oz-V’s Phase 3 study design. The company is optimistic about the potential for accelerated approval of Oz-V and anticipates transformational value creation from its ongoing clinical activities.

Looking ahead, BioAtla remains committed to its strategic goals, including the completion of its Phase 2 trials and the pursuit of partnerships to support its clinical activities. The company expects to continue reducing its R&D expenses and cash burn as it progresses towards these milestones.